A Novel In Situ Vaccine: Intratumoral Flt3L and Poly-ICLC with Low-Dose Radiotherapy

Lymphomas are the 5th most common cancer in the United States, 40% of these cases are indolent non-Hodgkin's lymphoma (iNHL) and are incurable with standard therapy. In a previous trial of in situ vaccination (ISV) in iNHLs, in which intratumoral CpG, the TLR9 agonist, was combined with low dose radiation to induce a systemic immune response against tumor, induction of tumor-specific CD8 T cell responses and durable clinical remissions of patients ’ untreated sites of disease was seen in some patients.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Thomas Marron, Nina Bhardwaj, Linda Hammerich, Fiby George, Seunghee Kim-Schulze, Tibor Keler, Tom Davis, Elizabeth Crowley, Andres Salazar, Joshua Brody Source Type: research